Reperfusion Injury

CHICAGO — A drug derived from traditional Chinese medicine as an adjunct to guideline-directed therapy improved CV outcomes at 30 days and 1 year compared with placebo after revascularization, with no excess bleeding risk, a speaker reported.

The FDA announced that in response to its request, Penumbra has issued an urgent recall of reperfusion catheters for clot removal in patients with stroke due to risk for unexpected death or serious injury.

IV sodium nitrite administered by paramedics for out-of-hospital cardiac arrest had no effect on survival to hospital admission or discharge compared with placebo, according to data presented at the virtual American College of Cardiology Scientific Session.

Patients with chronic kidney disease who were assigned recombinant human C1 esterase inhibitor, or rhC1INH, before coronary angiography had a lower risk for renal injury compared with those assigned placebo, with a favorable safety profile, especially in those with multiple comorbidities, according to findings from the PROTECT study published in JACC: Cardiovascular Interventions.